company background image
OLMA

Olema Pharmaceuticals NasdaqGS:OLMA Stock Report

Last Price

US$4.06

Market Cap

US$162.5m

7D

-31.0%

1Y

-84.9%

Updated

12 Aug, 2022

Data

Company Financials +
OLMA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OLMA Stock Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

Olema Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Olema Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.06
52 Week HighUS$32.19
52 Week LowUS$2.00
Beta0
1 Month Change-11.74%
3 Month Change87.96%
1 Year Change-84.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-91.71%

Recent News & Updates

Aug 09

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Olema Pharmaceuticals press release (NASDAQ:OLMA): Q2 GAAP EPS of -$0.82 misses by $0.18. Cash, cash equivalents and marketable securities as of June 30, 2022, were $240.7 million.

Jul 21

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Olema Pharmaceuticals' (NASDAQ:OLMA) OP-1250 to treat certain patients with breast cancer. Specifically, the FDA designation for OP-1250 is to treat ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has progressed after one or more lines of endocrine therapy with at least one line given in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor. The company OP-1250 is currently being evaluated as a single agent in a phase 1/2 trial and in phase 1b study as a combination with palbociclib to treat certain patients breast cancer. OLMA +12.31% to $5.29 premarket July 21

Shareholder Returns

OLMAUS BiotechsUS Market
7D-31.0%1.2%3.2%
1Y-84.9%-21.7%-10.1%

Return vs Industry: OLMA underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: OLMA underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is OLMA's price volatile compared to industry and market?
OLMA volatility
OLMA Average Weekly Movement16.5%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: OLMA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: OLMA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200674Sean Bohenhttps://www.olema.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.

Olema Pharmaceuticals Fundamentals Summary

How do Olema Pharmaceuticals's earnings and revenue compare to its market cap?
OLMA fundamental statistics
Market CapUS$162.50m
Earnings (TTM)-US$95.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OLMA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$95.24m
Earnings-US$95.24m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.38
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did OLMA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OLMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OLMA?

Other financial metrics that can be useful for relative valuation.

OLMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does OLMA's PB Ratio compare to its peers?

OLMA PB Ratio vs Peers
The above table shows the PB ratio for OLMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average30x
CMRX Chimerix
8.5x-38.7%US$236.6m
OMGA Omega Therapeutics
1.5x3.0%US$236.4m
XOMA XOMA
1.7x60.5%US$229.9m
CLNN Clene
108.2x82.5%US$218.2m
OLMA Olema Pharmaceuticals
0.7x-15.0%US$162.5m

Price-To-Book vs Peers: OLMA is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (30x).


Price to Earnings Ratio vs Industry

How does OLMA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: OLMA is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is OLMA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OLMA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OLMA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of OLMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OLMA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OLMA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Olema Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-15.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OLMA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OLMA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OLMA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OLMA is forecast to have no revenue next year.

High Growth Revenue: OLMA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OLMA is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Olema Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-64.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OLMA is currently unprofitable.

Growing Profit Margin: OLMA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OLMA is unprofitable, and losses have increased over the past 5 years at a rate of 64.3% per year.

Accelerating Growth: Unable to compare OLMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OLMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: OLMA has a negative Return on Equity (-40.31%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Olema Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OLMA's short term assets ($243.0M) exceed its short term liabilities ($12.3M).

Long Term Liabilities: OLMA's short term assets ($243.0M) exceed its long term liabilities ($2.0M).


Debt to Equity History and Analysis

Debt Level: OLMA is debt free.

Reducing Debt: OLMA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OLMA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: OLMA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 64% each year.


Discover healthy companies

Dividend

What is Olema Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OLMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OLMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OLMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OLMA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OLMA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Sean Bohen (55 yo)

1.92yrs

Tenure

US$3,323,550

Compensation

Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD3.32M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OLMA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: OLMA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Olema Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Olema Pharmaceuticals, Inc.
  • Ticker: OLMA
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$162.502m
  • Shares outstanding: 40.03m
  • Website: https://www.olema.com

Number of Employees


Location

  • Olema Pharmaceuticals, Inc.
  • 512 2nd Street
  • 4th Floor
  • San Francisco
  • California
  • 94107
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.